BRAF and colorectal carcinoma: DiFi and WiDr CRC cells, as well as the BRAF V600E-mutated cell line (JVE207), were treated with a MAPK (mitogen-activated protein kinase) pathway inhibitor, the REV1 inhibitor or their combination.